Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention

Cardiovascular disease (CVD) and cancer are leading causes of mortality and morbidity worldwide. Strategies to improve their treatment and prevention are global priorities and major focus of World Health Organization's joint prevention programs. Emerging evidence suggests that modifiable risk f...

Full description

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 263; pp. 343 - 351
Main Authors Masoudkabir, Farzad, Sarrafzadegan, Nizal, Gotay, Carolyn, Ignaszewski, Andrew, Krahn, Andrew D., Davis, Margot K., Franco, Christopher, Mani, Arya
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.08.2017
Subjects
Online AccessGet full text
ISSN0021-9150
1879-1484
1879-1484
DOI10.1016/j.atherosclerosis.2017.06.001

Cover

More Information
Summary:Cardiovascular disease (CVD) and cancer are leading causes of mortality and morbidity worldwide. Strategies to improve their treatment and prevention are global priorities and major focus of World Health Organization's joint prevention programs. Emerging evidence suggests that modifiable risk factors including diet, sedentary lifestyle, obesity and tobacco use are central to the pathogenesis of both diseases and are reflected in common genetic, cellular, and signaling mechanisms. Understanding this important biological overlap is critical and may help identify novel therapeutic and preventative strategies for both disorders. In this review, we will discuss the shared genetic and molecular factors central to CVD and cancer and how the strategies commonly used for the prevention of atherosclerotic vascular disease can be applied to cancer prevention. [Display omitted] •Cardiovascular disease (CVD) and cancer are leading causes of mortality and morbidity worldwide.•CVD and cancer have common risk factors and shared genetics and molecular mechanisms that are central to their pathogenesis.•The shared pathways of CVD and cancer are potential targets for development of novel drugs for joint pharmacologic prevention of CVD and cancer.•A growing body of evidence supports a role for aspirin, statins, ACE inhibitors/ARBs, metformin, and TZDs in cancer prevention.•Both pharmacologic and non-pharmacologic preventive programs should be directed jointly at CVD and cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
FMK was responsible for writing the draft of the manuscript, creating the figure and tables and performing major revision of the manuscript. NS developed the idea, wrote some parts, edited the whole manuscript and supervised the whole project. CG edited the whole manuscript and wrote some parts. AI contributed in idea development and edited the manuscript. AK was responsible for editing the whole manuscript and writing some parts. MD wrote the cardio-oncology section. CF critically edited the whole manuscript and shortened the manuscript. AM was responsible for scientific support of the genetic and molecular pathways and did the major revisions.
Author contributions
ISSN:0021-9150
1879-1484
1879-1484
DOI:10.1016/j.atherosclerosis.2017.06.001